Intramuscularly Administered SNAP-TI Nanoparticles Induce Systemic Antigen-Specific Tolerance
Time: 3:00 pm
day: Day One PM Non-Cell Based Approaches
Details:
- SNAP-TI leverages self-assembly to codeliver multiple antigens and an immunomodulator in nanoparticles optimized for targeting all major APC populations in draining lymph nodes, spleen and liver following intramuscular injection
- Enhanced APC uptake together with codelivered immunomodulator promote increased Treg/Teff ratio associated with efficacy in animal models of vitiligo, T1D and EAE
- SNAP-TI candidate for celiac disease entering clinical testing in 2024
